DeepMed Research

BARBARA ANN KARMANOS CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1995-01-01

Employees: 5K

Market Cap: -

Website: http://www.karmanos.org

Clinical Trials

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

Not Applicable

Completed

Conditions: Breast Cancer
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Nausea and Vomiting
Neuroblastoma
Ovarian Cancer
Testicular Germ Cell Tumor

Interventions: Drug: Aprepitant
Drug: Cyclophosphamide
Drug: Dexamethasone
Drug: Granisetron hydrochloride

First Posted Date: 2006-02-17

Last Posted Date: 2016-03-15

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 40

Registration Number: NCT00293384

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: bortezomib

First Posted Date: 2006-02-07

Last Posted Date: 2013-11-19

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 15

Registration Number: NCT00288028

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

Phase 1

Withdrawn

Conditions: Non-small Cell Lung Cancer

First Posted Date: 2005-12-22

Last Posted Date: 2013-04-16

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00268255

Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: capecitabine
Drug: docetaxel

First Posted Date: 2005-11-24

Last Posted Date: 2014-03-06

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00258284

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: capecitabine
Procedure: Surgery, chemotherapy and/or radiotherapy

First Posted Date: 2005-11-24

Last Posted Date: 2023-03-10

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 35

Registration Number: NCT00258310

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Dietary Supplement: ascorbic acid
Drug: arsenic trioxide
Drug: bortezomib
Drug: dexamethasone
Drug: thalidomide
Drug: Aspirin

First Posted Date: 2005-11-24

Last Posted Date: 2013-04-29

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 5

Registration Number: NCT00258245

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer

Phase 3

Withdrawn

Conditions: Prostate Cancer

First Posted Date: 2005-11-24

Last Posted Date: 2013-04-08

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00258466

Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2005-11-24

Last Posted Date: 2013-04-08

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00258232

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Cisplatin
Drug: Gleevec™
Drug: irinotecan

First Posted Date: 2005-11-04

Last Posted Date: 2013-04-29

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 6

Registration Number: NCT00248482

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: docetaxel
Drug: Gemcitabine

First Posted Date: 2005-11-04

Last Posted Date: 2019-03-05

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 36

Registration Number: NCT00248560

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy